Format

Send to

Choose Destination
See comment in PubMed Commons below
Nat Rev Cancer. 2015 Aug;15(8):457-72. doi: 10.1038/nrc3973.

Evolving synergistic combinations of targeted immunotherapies to combat cancer.

Author information

1
Centro de Investigación Médica Aplicada (CIMA) and Clínica Universitaria, Avenida Pío XII, 55 E-31008, Universidad de Navarra, Pamplona, Spain.
2
Bristol-Myers Squibb, 3551 Lawrenceville Princeton, New Jersey 08648, USA.
3
Bristol-Myers Squibb Biologics Discovery California, 700 Bay Road, Redwood City, California 94063, USA.
4
The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.

Abstract

Immunotherapy has now been clinically validated as an effective treatment for many cancers. There is tremendous potential for synergistic combinations of immunotherapy agents and for combining immunotherapy agents with conventional cancer treatments. Clinical trials combining blockade of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) may serve as a paradigm to guide future approaches to immuno-oncology combination therapy. In this Review, we discuss progress in the synergistic design of immune-targeting combination therapies and highlight the challenges involved in tailoring such strategies to provide maximal benefit to patients.

PMID:
26205340
DOI:
10.1038/nrc3973
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Support Center